NAFDAC Joins African Medicines Agency: A Strategic Leap to Combat Counterfeit Drugs and Transform Continental Healthcare
The National Agency for Food and Drug Administration and Control (NAFDAC) has officially joined the African Medicines Agency (AMA), marking a pivotal step in strengthening medicine regulation, combating substandard and falsified medical products, and improving access to quality healthcare across Africa. This collaboration, announced during a one-day stakeholders’ engagement in Abuja on NAFDAC’s regulatory transformation journey and Nigeria’s commitment to the AMA treaty, signals a new era of harmonized oversight and cross-border cooperation.
Why This Partnership Matters: The Scale of the Counterfeit Drug Crisis
Counterfeit and substandard medicines represent a global public health emergency, with the World Health Organization estimating that 1 in 10 medical products in low- and middle-income countries is falsified or substandard. In Africa, the problem is particularly acute due to fragmented regulatory systems, weak supply chains, and limited enforcement capacity. These fake drugs not only fail to treat diseases but can cause severe harm, including antimicrobial resistance, organ failure, and death. By joining AMA, NAFDAC aligns Nigeria with a continental framework designed to tackle these challenges through unified standards, shared intelligence, and coordinated action.
NAFDAC’s Role and Ongoing Reforms
Speaking at the event, NAFDAC Director-General, Prof. Mojisola Adeyeye, emphasized that the agency’s participation in AMA would promote harmonized regulatory standards and deepen collaboration among African countries. She noted that Nigeria’s pharmaceutical industry—comprising over 200 pharmaceutical companies—has the capacity to support medicine production and distribution across the continent. However, she stressed that ongoing reforms by NAFDAC are already reducing the prevalence of substandard and falsified medicines in the country, but the fight against counterfeit drugs requires sustained vigilance and cooperation.
“Fake medicines pose serious health risks to the public. Nigerians must avoid buying medicines from unverified sources and should patronise only licensed pharmacies,” Adeyeye said. She also advised consumers to demand receipts when purchasing drugs, adding that manufacturers are being sensitised against distributing products through informal channels. This consumer-focused advice is critical: in many African markets, up to 30% of medicines are sold through unregulated street vendors or open markets, bypassing quality checks entirely.
The African Medicines Agency: A Continental Framework for Regulatory Harmonization
Dr. Mimi Darko, Director-General of the African Medicines Agency, described the agency as a continental framework established to harmonise the regulation of medical products and strengthen national regulatory authorities across Africa. She explained that fragmented regulatory systems on the continent have slowed access to medicines and increased costs for both manufacturers and consumers. For example, a drug approved in one country may face years of separate, duplicative reviews in another, delaying patient access and raising prices by up to 40%.
Darko outlined that the AMA would introduce a “one application, one regime” system to streamline medicine approvals and improve access to safe and effective medical products. This system will allow manufacturers to submit a single dossier for review by a panel of experts from multiple countries, reducing approval times from years to months. Additionally, the agency will establish a continental database for monitoring the quality and safety of medicines, enabling real-time tracking of adverse events and counterfeit alerts. The AMA will also focus on regulating complex medical products, including vaccines, biomedical devices, and emerging technologies like gene therapies and digital health tools.
Practical Example: How the “One Application, One Regime” System Works
Consider a manufacturer in South Africa that develops a new antimalarial drug. Currently, to market the drug in Nigeria, Kenya, and Ghana, the company must submit separate applications to each country’s regulatory authority, each with its own requirements, timelines, and fees. Under the AMA’s system, the manufacturer would submit a single application to the AMA, which would coordinate a joint review by experts from all three countries. The result: faster approvals, lower costs, and consistent safety standards across borders. This efficiency is especially vital for pandemic response, where speed can save lives.
African Union’s Endorsement and the Path Forward
In her remarks, the African Union Commissioner for Health, Humanitarian Affairs and Social Development, Amma Twum-Amoah, commended Nigeria for joining the agency, describing the development as a major boost to Africa’s health security and pharmaceutical industrialisation. She explained that the AMA would complement, rather than replace, national regulatory authorities by promoting shared expertise, collaboration, and coordinated regulatory action across member states. This means NAFDAC retains its authority over domestic regulation while gaining access to AMA’s resources, training, and intelligence networks.
Twum-Amoah also urged African countries yet to ratify the treaty to do so, stressing that ratification must be followed by effective implementation. As of early 2025, only 15 of the African Union’s 55 member states have ratified the AMA treaty, leaving significant gaps in coverage. Nigeria’s ratification—as Africa’s most populous nation and largest economy—provides critical momentum for the agency’s operationalization.
Stakeholder Call to Action: Collaboration is Key
Stakeholders at the engagement called for stronger collaboration among regulators, manufacturers, and consumers to curb counterfeit medicines, improve regulatory efficiency, and expand access to safe and affordable drugs across the continent. This includes public awareness campaigns to educate consumers on verifying drug authenticity (e.g., checking NAFDAC registration numbers), incentivizing manufacturers to adopt tamper-evident packaging, and empowering customs officials with portable testing devices to screen imports at borders.
Related
Conclusion: A Transformative Step for African Health Security
NAFDAC’s membership in the African Medicines Agency is more than a bureaucratic formality—it is a strategic commitment to saving lives, reducing healthcare costs, and building a resilient pharmaceutical ecosystem. By harmonizing regulations, sharing data, and fostering trust among nations, the AMA offers a concrete path toward a future where every African has access to safe, effective, and affordable medicines. For consumers, the message is clear: demand quality, buy from licensed sources, and support the institutions working to protect your health.
All credit goes to the original article. For more information, read the: Source link